[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Ozmosi [@OzmosiHealth](/creator/twitter/OzmosiHealth) on x 2633 followers Created: 2025-07-23 01:02:12 UTC $ABVX, PARIS:ABVX, PARIS:FR Abivax reports successful Phase X outcomes in ABTECT 8-Week trials for Obefazimod, a novel miR-124 enhancer for treatment of Ulcerative Colitis. More Info: $XBI $IBB $XPH $PPH  XXX engagements  **Related Topics** [$pph](/topic/$pph) [$xph](/topic/$xph) [$ibb](/topic/$ibb) [$xbi](/topic/$xbi) [more info](/topic/more-info) [$abvx](/topic/$abvx) [Post Link](https://x.com/OzmosiHealth/status/1947824536189342085)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Ozmosi @OzmosiHealth on x 2633 followers
Created: 2025-07-23 01:02:12 UTC
$ABVX, PARIS:ABVX, PARIS:FR Abivax reports successful Phase X outcomes in ABTECT 8-Week trials for Obefazimod, a novel miR-124 enhancer for treatment of Ulcerative Colitis.
More Info: $XBI $IBB $XPH $PPH
XXX engagements
/post/tweet::1947824536189342085